The outlook for the day is a shaky start as the landscape of global indices has turned red after the release of a slew of dismal economic data and an inverted yield curve in the US bonds created concerns of a global economic slowdown. At the time of writing, the SGX Nifty was trading at 11,418, down by 51 points.

Read on to know which stocks will be in focus on account of approaching their ex-date for bonuses, rights issue, buyback and dividends during the week.

The index has shown the first sign of weakness and formed bearish engulfing candle on the daily scale. The bearish engulfing candlestick pattern is considered to be a bearish reversal pattern and usually occurs at the top of an uptrend.

The stock of City Union Bank Limited has given a downward sloping trendline breakout on Friday formed by connecting swing highs from August 31, 2018.

The stocks that are likely to witness significant movement on the bourses on March 25 are Greenlam Industries, Alkem Laboratories, Cadila Healthcare, Garden Reach Shipbuilders & Engineers and Ramco Cements.

As every coin has two sides and mutual funds are no different in that sense. Fund managers not only buy but also sell. It becomes equally important to know what they are selling. So, let’s find out.

Alkem Laboratories shed 2 per cent at closing as the company received a pre-approval inspection for a product manufactured at its plant in St. Louis, US.

The Indian indices closed Friday's trading session with sharp fall after initial gains. BSE Sensex and Nifty ended down by nearly 0.6 per cent and 0.56 per cent on the last day of the week, after registering handsome gains on a weekly basis.

Pharma major Lupin launched Levothyroxine tablets for which is had earlier received USFDA approval. The tablets are used to treat hypothyroidism and pituitary thyrotropin suppression.

Caplin Steriles, a 100 per cent subsidiary of Caplin Point Laboratories has received final approval by the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Glycopyrrolate injection USP.